The new prices are valid through December 2024 and present price reductions up to 55% compared to the previous price of US$289 for a 6-month treatment course of bedaquiline.
30 August 2023, Geneva, Switzerland - The Stop TB Partnership’s Global Drug Facility (GDF) announced price reductions up to 55% for bedaquiline, a critical drug used to treat drug-resistant TB.
The new, reduced bedaquiline prices - secured through an open, competitive tender and valid through December 2024 - are as follows:
These new bedaquiline prices are available to the vast majority of low- and middle-income countries and reflect a 55% and 33% price decrease for Johnson & Johnson and Lupin, respectively, compared to the previous price of US$289 for a 6-month treatment course of bedaquiline.
Around 450,000 people are estimated to have drug-resistant TB. The GDF estimates its lower bedaquiline prices will generate US$8 million in savings over the 16-month contract period, an amount sufficient to procure more than 51,000 additional bedaquiline treatments and potentially support thousands more people to access critical treatment for drug-resistant TB.
Read the full announcement here.